Cleveland Clinic Cole Eye Institute Chairman and CATT study chair discusses the story behind and his current thoughts on the landmark trial that looked at the effectiveness of two important drugs used to treat AMD.

Year one results for the "Comparison of AMD Treatment Trials" or CATT, were released in March 2011. Led by Cole Eye Institute chairman Dr. Daniel F. Martin, the head-to-head trial compared the effectiveness of ranibizumab (Lucentis┬«) and bevacizumab (Avastin®), two anti-VEGF agents of intravitreal injections used to treat patients with neovascular age-related macular degeneration (AMD).

Conducted at 44 centers across the country, the trial not only yielded important results about the effectiveness of these two drugs, but it also uncovered critical findings regarding the administering of as-needed injections with monthly monitoring.